In late 2017, a study was published in Acta Reumatologica Portuguesa evaluating the effect adalimumab (Humira), an anti–tumor necrosis factor therapy in the treatment of patients with both short- and long-term psoriatic arthritis (PsA) disease duration.
In late 2017, a study was published in Acta Reumatologica Portuguesa evaluating the effect of adalimumab (Humira), an anti—tumor necrosis factor therapy, in the treatment of patients with both short- and long-term psoriatic arthritis (PsA) disease duration.
This study was a multicenter, non-interventional, open cohort trial that utilized data from the Rheumatic Diseases Portuguese Register. Patients included in the study were adults with PsA who were diagnosed according to the Classification Criteria for Psoriatic Arthritis, were registered in the database between June 2008 and June 2016, and had received adalimumab therapy for 3 or more months.
In total, 126 patients were included in the study. Participants with early PsA had a mean disease duration of 2.6 years (±1.3 years) and were significantly younger and began treatment with biologics earlier than patients with late PsA. Conversely, patients with late-stage PsA had a mean disease duration of 13.4 years (±8.1 years).
A Psoriasis Arthritis Response Criteria (PsARC) response was achieved by 72.9% of patients treated with adalimumab at 3 months. Of the participants receiving adalimumab at month 24, 85.4% had a PsARC response. More patients with early PsA achieved PsARC at 3 months than did patients with late PsA (88% versus 62.2%; P =.022) and 24 months (100% versus 75.8%; P =.044).
The early PsA group achieved, on average, a PsARC response 3.8 months after initial treatment with adalimumab; the mean time to PsARC response in patients with late PsA was 7.4 months.
It is important to note that, during the study follow-up, 51 patients (37.8%) discontinued treatment with adalimumab. The mean duration of therapy until discontinuation was 25.7 months (± 21.2 months): 14.7 months (±16.5 months) for patients with early PsA and 29.9 months (± 22.6 months) for those with late PsA (P =.033).
The most common reason for therapy discontinuation was lack of efficacy, and the proportion of patients with early PsA (31.7%) and late PsA (40.0%) who discontinued adalimumab was similar.
Researchers found that, in this real-world clinical setting, patients with PsA who had a shorter disease duration achieved better results after treatment with adalimumab than did patients with a longer disease duration. This finding adds support to the idea that shorter symptom duration and earlier treatment with adalimumab could lead to a more favorable outcome in patients with PsA. Researchers did note, however, that further studies are needed to confirm these results.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.